First-in-human study of AMG 820, a monoclonal anti-colony-stimulating factor 1 receptor antibody, in patients with advanced solid tumors
Purpose: Binding of colony-stimulating factor 1 (CSF1) ligand to the CSF1 receptor (CSF1R) regulates survival of tumor-associated macrophages, which generally promote an immunosuppressive tumor microenvironment. AMG 820 is an investigational, fully human CSF1R antibody that inhibits binding of the l...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
October 2017
|
| In: |
Clinical cancer research
Year: 2017, Jahrgang: 23, Heft: 19, Pages: 5703-5710 |
| ISSN: | 1557-3265 |
| DOI: | 10.1158/1078-0432.CCR-16-3261 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1158/1078-0432.CCR-16-3261 Verlag, Volltext: http://clincancerres.aacrjournals.org/content/23/19/5703 
|
| Verfasserangaben: | Kyriakos P. Papadopoulos, Larry Gluck, Lainie P. Martin, Anthony J. Olszanski, Anthony W. Tolcher, Gataree Ngarmchamnanrith, Erik Rasmussen, Benny M. Amore, Dirk Nagorsen, John S. Hill, and Joe Stephenson Jr. |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1582721262 | ||
| 003 | DE-627 | ||
| 005 | 20230427193302.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 181108s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/1078-0432.CCR-16-3261 |2 doi | |
| 035 | |a (DE-627)1582721262 | ||
| 035 | |a (DE-576)512721262 | ||
| 035 | |a (DE-599)BSZ512721262 | ||
| 035 | |a (OCoLC)1341022589 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Papadopoulos, Kyriakos P. |e VerfasserIn |0 (DE-588)1170926908 |0 (DE-627)1040244440 |0 (DE-576)512720649 |4 aut | |
| 245 | 1 | 0 | |a First-in-human study of AMG 820, a monoclonal anti-colony-stimulating factor 1 receptor antibody, in patients with advanced solid tumors |c Kyriakos P. Papadopoulos, Larry Gluck, Lainie P. Martin, Anthony J. Olszanski, Anthony W. Tolcher, Gataree Ngarmchamnanrith, Erik Rasmussen, Benny M. Amore, Dirk Nagorsen, John S. Hill, and Joe Stephenson Jr. |
| 264 | 1 | |c October 2017 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 08.11.2018 | ||
| 520 | |a Purpose: Binding of colony-stimulating factor 1 (CSF1) ligand to the CSF1 receptor (CSF1R) regulates survival of tumor-associated macrophages, which generally promote an immunosuppressive tumor microenvironment. AMG 820 is an investigational, fully human CSF1R antibody that inhibits binding of the ligands CSF1 and IL34 and subsequent ligand-mediated receptor activation. This first-in-human phase I study evaluated the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of AMG 820. Experimental Design: Adult patients with relapsed or refractory advanced solid tumors received intravenous AMG 820 0.5 mg/kg once weekly or 1.5 to 20 mg/kg every 2 weeks until disease progression, adverse event (AE), or consent withdrawal. Results: Twenty-five patients received ≥1 dose of AMG 820. AMG 820 was tolerated up to 20 mg/kg; the MTD was not reached. One dose-limiting toxicity was observed (20 mg/kg; nonreversible grade 3 deafness). Most patients (76%) had treatment-related AEs; the most common were periorbital edema (44%), increased aspartate aminotransferase (AST; 28%), fatigue (24%), nausea (16%), increased blood alkaline phosphatase (12%), and blurred vision (12%). No patients had serious or fatal treatment-related AEs; 28% had grade ≥3 treatment-related AEs. Grade 3 AST elevations resolved when treatment was withheld. AMG 820 showed linear pharmacokinetics, with minimal accumulation (<2-fold) after repeated dosing. Pharmacodynamic increases in serum CSF1 concentrations and reduced numbers of skin macrophages were observed. Best response was stable disease in 8 patients (32%). Conclusions: AMG 820 was tolerated with manageable toxicities up to 20 mg/kg every 2 weeks. Pharmacodynamic response was demonstrated, and limited antitumor activity was observed. | ||
| 700 | 1 | |a Nagorsen, Dirk |d 1974- |e VerfasserIn |0 (DE-588)12152471X |0 (DE-627)081364245 |0 (DE-576)183363094 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical cancer research |d Philadelphia, Pa. [u.a.] : AACR, 1995 |g 23(2017), 19, Seite 5703-5710 |h Online-Ressource |w (DE-627)325489971 |w (DE-600)2036787-9 |w (DE-576)094502234 |x 1557-3265 |7 nnas |a First-in-human study of AMG 820, a monoclonal anti-colony-stimulating factor 1 receptor antibody, in patients with advanced solid tumors |
| 773 | 1 | 8 | |g volume:23 |g year:2017 |g number:19 |g pages:5703-5710 |g extent:8 |a First-in-human study of AMG 820, a monoclonal anti-colony-stimulating factor 1 receptor antibody, in patients with advanced solid tumors |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1158/1078-0432.CCR-16-3261 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://clincancerres.aacrjournals.org/content/23/19/5703 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20181108 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 12152471X |a Nagorsen, Dirk |m 12152471X:Nagorsen, Dirk |d 60000 |e 60000PN12152471X |k 0/60000/ |p 9 | ||
| 999 | |a KXP-PPN1582721262 |e 3030665887 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 08.11.2018"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"1582721262","language":["eng"],"person":[{"role":"aut","display":"Papadopoulos, Kyriakos P.","roleDisplay":"VerfasserIn","given":"Kyriakos P.","family":"Papadopoulos"},{"given":"Dirk","family":"Nagorsen","role":"aut","display":"Nagorsen, Dirk","roleDisplay":"VerfasserIn"}],"title":[{"title_sort":"First-in-human study of AMG 820, a monoclonal anti-colony-stimulating factor 1 receptor antibody, in patients with advanced solid tumors","title":"First-in-human study of AMG 820, a monoclonal anti-colony-stimulating factor 1 receptor antibody, in patients with advanced solid tumors"}],"physDesc":[{"extent":"8 S."}],"relHost":[{"name":{"displayForm":["American Association for Cancer Research"]},"origin":[{"publisher":"AACR","dateIssuedKey":"1995","dateIssuedDisp":"1995-","publisherPlace":"Philadelphia, Pa. [u.a.]"}],"id":{"zdb":["2036787-9"],"eki":["325489971"],"issn":["1557-3265"]},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title":"Clinical cancer research","title_sort":"Clinical cancer research"}],"disp":"First-in-human study of AMG 820, a monoclonal anti-colony-stimulating factor 1 receptor antibody, in patients with advanced solid tumorsClinical cancer research","type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 08.06.2023","Fortsetzung der Druck-Ausgabe"],"recId":"325489971","corporate":[{"role":"isb","display":"American Association for Cancer Research","roleDisplay":"Herausgebendes Organ"}],"language":["eng"],"pubHistory":["1.1995 -"],"part":{"issue":"19","pages":"5703-5710","year":"2017","extent":"8","volume":"23","text":"23(2017), 19, Seite 5703-5710"}}],"name":{"displayForm":["Kyriakos P. Papadopoulos, Larry Gluck, Lainie P. Martin, Anthony J. Olszanski, Anthony W. Tolcher, Gataree Ngarmchamnanrith, Erik Rasmussen, Benny M. Amore, Dirk Nagorsen, John S. Hill, and Joe Stephenson Jr."]},"origin":[{"dateIssuedDisp":"October 2017","dateIssuedKey":"2017"}],"id":{"eki":["1582721262"],"doi":["10.1158/1078-0432.CCR-16-3261"]}} | ||
| SRT | |a PAPADOPOULFIRSTINHUM2017 | ||